IP Library Granted Patent US 8,034,772
Granted Patent B2
US 8,034,772 · App. 12/322,800 · Granted Oct 11, 2011

Inhibitor of vascular endothelial cell growth factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,772
App. No.
12/322,800
Granted
Oct 11, 2011
Kind
B2
Abstract

The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.

Claims (4)

1. A soluble VEGF inhibitor protein in substantially pure form which comprises the amino acid sequence as set forth in SEQ ID NO: 12.

2. A composition comprising the inhibitor of claim 1 and a pharmaceutically acceptable carrier.

3. A soluble VEGF inhibitor protein in substantially pure form which consists of the amino acid sequence as set forth in SEQ ID NO: 12.

4. A composition comprising the inhibitor of claim 3 and a pharmaceutically acceptable carrier.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2012
From: GREEN, DUSTIN LYLE; NAGAMPALLI, NARASIMHA RAO S.S.
To: MICROSOFT CORPORATION
Reel/Frame 028876/0041 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 27, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023852/0595 →